Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	2.41	5.99	1.19	4.6
Cash & Short-Term Investments	2.41	5.99	1.19	4.6
Cash Growth	-60.78%	404.72%	-74.17%	-
Other Current Assets	1.65	0.65	1.06	0.38
Total Current Assets	4.07	6.64	2.25	4.98
Net Property, Plant & Equipment	0.4	0.44	0.56	0.25
Other Long-Term Assets	0.13	0.14	0.05	0.03
Total Assets	4.6	7.22	2.86	5.26
Accounts Payable	1.76	1.7	1.72	0.32
Accrued Expenses	0.56	0.88	0.64	1.57
Short-Term Debt	1.55	-	1	-
Current Portion of Leases	0.19	0.18	0.16	0.11
Other Current Liabilities	-	-	0	0.2
Total Current Liabilities	4.06	2.76	3.52	2.2
Long-Term Debt	-	1.57	2.96	-
Long-Term Leases	0.25	0.29	0.37	0.06
Total Long-Term Liabilities	0.25	1.85	3.33	0.06
Total Liabilities	4.31	4.61	6.85	2.26
Common Stock	0.05	0.04	0	-
Additional Paid-in Capital	58.14	57.73	39.26	11.34
Retained Earnings	-57.9	-55.17	-43.25	-26.81
Shareholders' Equity	0.29	2.6	-3.99	-15.48
Total Liabilities & Equity	4.6	7.22	2.86	5.26
Total Debt	1.99	2.04	4.49	0.17
Net Cash (Debt)	0.42	3.96	-3.3	4.42
Net Cash Growth	-89.28%	-	-	-
Net Cash Per Share	0.21	2.98	-79.36	593.95
Book Value	0.29	2.6	-3.99	-15.48
Book Value Per Share	0.14	1.96	-95.81	-2077.75
Tangible Book Value	0.29	2.6	-3.99	-15.48
Tangible Book Value Per Share	0.14	1.96	-95.81	-2077.75

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q